SyncThink

What SyncThink does

SyncThink, operating under the legal entity NeuroSync Inc. and headquartered in Palo Alto, California, is a private digital health company that has built the FDA-cleared EYE-SYNC platform — a wireless VR-based system that objectively measures eye movements to assess brain health, detect concussions, and support clinical decision-making. The platform combines proprietary XR hardware, AI-powered analytics, and customizable reports, with each assessment reportedly completed in under one minute and validated at a 0.9 test-retest reliability. Independent research validation of the underlying quantification methods is highlighted on the company's marketing materials.

The company sells to four primary verticals: Healthcare Providers (hospitals and specialty clinics for concussion assessment, vestibular therapy, and brain health diagnostics), Sports Organizations (university and professional athletic programs for athlete safety), Military (active duty cognitive performance optimization), and Biopharma (CNS clinical trial endpoints and drug response monitoring). Named customers include Massachusetts General Hospital, Houston Methodist, Sutter Health, St. David's Medical Center, Rice University, Georgia Tech, and Virginia Tech, alongside specialty clinics such as the Kutcher Clinic for Sports Neurology and the Kaizen Brain Center.

The business model is enterprise B2B direct sales with a "Request a Demo" engagement motion, monetizing through bundled VR hardware and proprietary software/analytics sales. Pricing is not publicly disclosed, consistent with a consultative sales approach targeting larger institutional contracts. The company was founded in 2009, remains private, and operates with a 1–10 employee team, with disclosed funding of approximately $3.6 million across rounds from Quadrant Management, Oceanic Partners, MassChallenge, and StartUp Health, the most recent dated 2019.

Name

SyncThink

Legal name

NeuroSync Inc.

Website

https://syncthink.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

SyncThink (legal: NeuroSync Inc.) provides the FDA-cleered [cleared] EYE-SYNC VR-based eye-tracking platform for objective brain health and concussion assessment. It serves healthcare providers, sports organizations, the military, and biopharma customers through enterprise direct sales.

Ownership category

akta.pro rank

Product category

Digital Health Neurotechnology

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Industrial Instruments For Measurement, Display, And Control (3823), Computer Peripheral Equipment, Nec (3577)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

akta.pro secondary industries

Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Smart Fitness & Training Devices (Connected Fitness Sensors, Smart Jump Ropes, etc.) (CRACAQAH), VR/XR Hardware & Accessories (Headsets, Controllers, Trackers, Haptics) (MPAFAGAG)

Keywords

• Digital health diagnostics
• VR eye tracking platform
• Concussion assessment technology
• Brain health analytics
• Neurotechnology solutions

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. VR Platform and Software Sales: Sale of VR hardware (XR hardware) combined with proprietary software and analytics. The platform is customized for various use cases including healthcare, sports, military, and biopharma applications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

SyncThink sells the EYE-SYNC platform, an FDA-cleared, VR-based eye-tracking assessment system that objectively measures eye movements to evaluate brain health, diagnose concussions, and support clinical and performance decision-making. The offering bundles wireless XR hardware with proprietary AI-powered software and analytics and customizable reports, delivered as enterprise solutions for healthcare providers, sports organizations, the military, and biopharma companies. Assessments complete in under one minute with 0.9 test-retest reliability.

Product overview

NeuroSync offers a digital health platform for assessing brain health and optimizing performance. The core product is EYE-SYNC, an FDA-cleared VR-based system that objectively measures eye movements to detect neurological deficits and support clinical decision-making. The platform consists of wireless XR Hardware, Software & Analytics powered by AI, and Customizable Reports. The product portfolio includes Neuro Health for healthcare and clinical research applications, and Brain Performance for sports, military, and high-performance optimization use cases. All assessments are completed in under a minute with validated metrics showing 0.9 test-retest reliability.

Differentiator

Problem solved

Functional benefit

Brands

• EYE-SYNC: FDA-cleared VR-based eye tracking assessment platform for concussion diagnosis and brain health monitoring

Products and services

• EYE-SYNC FDA-cleared VR-based assessment platform that objectively measures eye movements to evaluate brain health, detect concussions, and support clinical decision-making. The system uses proprietary algorithms and quantification methods validated in independent research, with assessments completed in under one minute and 0.9 test-retest reliability. Targeted at healthcare providers, sports programs, military, and biopharma researchers.
• Neuro Health Brain health assessment solution designed for healthcare providers to support advanced patient care and clinical research, enabling objective diagnostics for neurological conditions. Targeted at hospitals, clinics, and academic medical centers running neurology and sports neurology practices.
• Brain Performance Performance optimization solution for sports organizations, military, and high-performance specialists to assess and optimize brain function and decision-making capabilities. Targeted at universities, professional sports teams, and defense organizations.

Quantifiable outcome

• 0.9 test-retest reliability for all assessments
• +1 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Oculogica: Oculogica develops FDA-cleared eye-tracking-based concussion and brain injury assessment tools that compete directly with SyncThink's EYE-SYNC platform. Both target the same clinical and sports customer base with VR-style eye-movement analytics.
• ImPACT Applications: ImPACT Applications is the dominant FDA-cleared computerized concussion assessment tool used across collegiate and professional sports. It competes with SyncThink in concussion management for schools, sports organizations, and military.
• BrainScope: BrainScope offers FDA-cleared EEG-based brain injury assessment devices used in hospital and military settings. It overlaps with SyncThink's clinical and military verticals as an objective brain-diagnostic alternative.
• King-Devick Technologies: King-Devick provides an eye-movement-based sideline concussion screening test used widely in sports. It targets the same athlete safety and concussion-management use case as SyncThink's Brain Performance module.
• Sway Medical: Sway Medical delivers mobile balance and reaction-time-based concussion assessment apps used by athletic programs. It competes for the same sports and university concussion-management budget as SyncThink.

Emerging players

• Mindstrong: Mindstrong developed digital biomarkers for neuropsychiatric conditions using smartphone-based interactions, an emerging alternative to clinic-visit brain health assessment. It overlaps with SyncThink's objective-neuroassessment positioning.
• Altoida: Altoida provides FDA Breakthrough-designated digital cognitive assessment tools using smartphone AR for neurodegenerative disease detection. It competes in the broader neurological-assessment category with SyncThink.
• C3 Logix: C3 Logix offers a multi-modal concussion assessment tablet platform used by schools and sports programs, overlapping with SyncThink's sports and education verticals.

Broad incumbents

• Akili Interactive: Akili Interactive delivers FDA-cleared digital therapeutics (EndeavorRx) for cognitive conditions, operating in the same digital-neurohealth category as SyncThink. Both pursue FDA-cleared digital solutions for brain health.

Others

• Tobii: Tobii is a global leader in eye-tracking technology and hardware, named as a partner/technology logo for NeuroSync. It is an enabling technology supplier to SyncThink's EYE-SYNC platform rather than a competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/SyncThinkInc
• Facebookfacebook.com/SyncThinkInc
• LinkedInlinkedin.com/company/sync-think

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SyncThink